Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Engineering the melanocortin-4 receptor to control constitutive and ligand-mediated G(S) signaling in vivo.

Srinivasan S, Santiago P, Lubrano C, Vaisse C, Conklin BR.

PLoS One. 2007 Aug 1;2(7):e668.

2.

Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand.

Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5163-8. Epub 2007 Mar 2.

3.

Development of hydrocephalus in mice expressing the G(i)-coupled GPCR Ro1 RASSL receptor in astrocytes.

Sweger EJ, Casper KB, Scearce-Levie K, Conklin BR, McCarthy KD.

J Neurosci. 2007 Feb 28;27(9):2309-17.

4.

Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goddard WA 3rd, Mailman RB.

Neuropharmacology. 2007 Feb;52(2):562-75. Epub 2006 Oct 24.

5.

Regulation of G proteins by human 5-HT1a receptor TM3/i2 and TM5/i3 loop peptides.

Thiagaraj HV, Ortiz TC, Devereaux MC Jr, Seaver B, Hall B, Parker KK.

Neurochem Int. 2007 Jan;50(1):109-18. Epub 2006 Sep 14.

PMID:
16973243
6.

5-hydroxytryptamine receptors in the human cardiovascular system.

Kaumann AJ, Levy FO.

Pharmacol Ther. 2006 Sep;111(3):674-706. Review.

PMID:
16960982
7.

Functional selectivity and classical concepts of quantitative pharmacology.

Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB.

J Pharmacol Exp Ther. 2007 Jan;320(1):1-13. Epub 2006 Jun 27. Review.

8.

Differential activation of G-proteins by mu-opioid receptor agonists.

Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M.

Br J Pharmacol. 2006 Mar;147(6):671-80.

9.

Molecular determinants in the second intracellular loop of the 5-hydroxytryptamine-1A receptor for G-protein coupling.

Kushwaha N, Harwood SC, Wilson AM, Berger M, Tecott LH, Roth BL, Albert PR.

Mol Pharmacol. 2006 May;69(5):1518-26. Epub 2006 Jan 12.

10.

The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus.

Crowell MD, Mathis C, Schettler VA, Yunus T, Lacy BE.

Neurogastroenterol Motil. 2005 Oct;17(5):738-43.

11.

A G(q/11)-coupled mutant histamine H(1) receptor F435A activated solely by synthetic ligands (RASSL).

Bruysters M, Jongejan A, Akdemir A, Bakker RA, Leurs R.

J Biol Chem. 2005 Oct 14;280(41):34741-6. Epub 2005 Jul 18.

12.

The origins of diversity and specificity in g protein-coupled receptor signaling.

Maudsley S, Martin B, Luttrell LM.

J Pharmacol Exp Ther. 2005 Aug;314(2):485-94. Epub 2005 Apr 1.

13.
14.

New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket.

Rivail L, Giner M, Gastineau M, Berthouze M, Soulier JL, Fischmeister R, Lezoualc'h F, Maigret B, Sicsic S, Berque-Bestel I.

Br J Pharmacol. 2004 Oct;143(3):361-70. Epub 2004 Sep 6.

15.
16.

[Feeding disorders in 5-HT4 receptor knockout mice].

Compan V, Charnay Y, Dusticier N, Daszuta A, Hen R, Bockaert J.

J Soc Biol. 2004;198(1):37-49. French.

PMID:
15146954
17.

Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology.

Brink CB, Harvey BH, Bodenstein J, Venter DP, Oliver DW.

Br J Clin Pharmacol. 2004 Apr;57(4):373-87. Review.

18.

The receptors for mammalian sweet and umami taste.

Zhao GQ, Zhang Y, Hoon MA, Chandrashekar J, Erlenbach I, Ryba NJ, Zuker CS.

Cell. 2003 Oct 31;115(3):255-66.

19.

Unravelling multiple ligand-activation binding sites using RASSL receptors.

Pauwels PJ.

Trends Pharmacol Sci. 2003 Oct;24(10):504-7. No abstract available.

PMID:
14559400

Supplemental Content

Support Center